




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61L 31/00, 15/32, 15/40, 27/00	A1	(11) International Publication Number: WO 95/18638 (43) International Publication Date: 13 July 1995 (13.07.95)
<p>(21) International Application Number: PCT/GB95/00008</p> <p>(22) International Filing Date: 4 January 1995 (04.01.95)</p> <p>(30) Priority Data: 9400163.3 6 January 1994 (06.01.94) GB</p> <p>(71) Applicant (for all designated States except US): ED GEISTLICH SOHNE AG FUR CHEMISCHE INDUSTRIE [CH/CH]; 6110 Wolhusen, CH-Lucerne (CH).</p> <p>(71) Applicant (for GB only): HOLMES, Michael, John [GB/GB]; Frank B. Dehn & CO., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GEISTLICH, Peter [CH/CH]; Kehrsitenstrasse 19, CH-6362 Stansstad (CH). ECKMAYER, Zdenek [DE/DE]; Rote Turmstrasse 28, D-69469 Weinheim (DE). BOYNE, Philip [US/US]; 11540 Hillcrest Road, Loma Linda, CA 92354 (US).</p> <p>(74) Common Representative: HOLMES, Michael, John; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).</p>		<p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>

(54) Title: **MEMBRANE**

(57) Abstract

The invention relates to a resorbable collagen membrane for use in guided tissue regeneration wherein one face of said membrane is fibrous thereby allowing cell growth thereon and the opposite face of said membrane is smooth, thereby inhibiting cell adhesion thereon. Such a membrane is of particular use in the treatment of wounds and lesions.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Membrane

The present invention is concerned with wound healing and in particular with the use of a collagen-containing membrane in guided tissue regeneration.

In any situation, such as following surgery especially oral or dental surgery, where wound healing is desirable, it has proved to be difficult to provide conditions which prevent ingrowth of other tissues into the area where regeneration is required. Thus, for example, where a substantial portion of a tooth root is removed due to decay or disease, it is desirable that healthy bone regeneration occurs to replace the bone tissue removed. However, it has been found that the cavity left by removal of the bone is quickly filled by connective tissue and that this ingrowth of connective tissue effectively prevents bone regeneration.

In order to overcome such difficulties the technique known as "guided tissue regeneration" has been developed. In this method a membrane is surgically inserted around the periphery of the wound cavity. The membrane prevents or hinders the invasion of the wound cavity by unwanted cell types and thus allows the preferred cells to grow into the cavity, thereby healing the wound.

Two membrane types are currently used in guided tissue regeneration:

- 1) Synthetic, non-resorbable PTFE membranes, such as Goretex (trade mark); and
- 2) Synthetic resorbable membranes formed from glycolide and lactide copolymers.

However, both of these membrane types suffer from serious disadvantages. The PTFE membrane, although exhibiting suitable characteristics of porosity, strength and flexibility, remains non-resorbable and therefore a second surgical operation is required to

remove the membrane. The requirement for further surgical procedures may be traumatic for the patient and may also damage the new tissue regenerated thus extending the treatment period.

The second membrane type is woven from glycolide and lactide copolymer fibres. Whilst this membrane is resorbable the breakdown products are irritant and this irritation may have undesirable effects on the patient.

Both prior art membranes act as filters, allowing liquids to pass freely and forming a barrier to cells. However, the membrane surface is not "cell-friendly", ie. it does not stabilise blood clots or support cell growth. Consequently, neither of the prior art membranes provide optimal conditions for cell growth and wound healing.

We have now found a membrane with ideal characteristics for guided tissue regeneration.

The present invention provides a resorbable collagen membrane for use in guided tissue regeneration wherein one face of said membrane is fibrous thereby allowing cell growth thereon and the opposite face of said membrane is smooth, thereby inhibiting cell adhesion thereon.

The two opposing sides or faces of the membrane thus have different textures which affect cell growth in different ways.

The smooth side acts as a barrier or filter to hinder cell ingrowth and will prevent undesirable cell types from colonising the cavity described by the membrane through physical separation. By contrast, the fibrous side of the membrane is haemostatic (stabilises blood clots) and aids cell growth by providing a suitable support for the new cells. In use, therefore, the membrane should be inserted with the smooth side outermost and the fibrous side facing the cells where regeneration is desired.

The membrane for use in guided tissue regeneration according to the present invention may be derived from a natural collagen membrane. Being derived from a natural source, the membrane for use in the present invention is totally resorbable in the body and does not form toxic degradation products.

Further the membrane has a tear strength and tear propagation resistance comparable to that of textile material in both wet and dry states. The membrane can therefore be surgically stitched if required. the membrane material is strongly hydrophilic and has good adherence when wet allowing several layers to be stacked together. When moist the material is very elastic which allows irregularly shaped or uneven wounds to be properly covered.

In both humans and animals, certain membranes surrounding important organs and separating different tissues and cells are made up of collagen. Examples of such membranes include the pericardium and placental membranes on the macroscale and basal membranes on the microscale.

Collagen products are now used widely in medicine. A variety of collagen materials are available including soluble collagen, collagen fibres, sponges, membranes and bone implants allowing diverse usage of this material, for example, collagen fibres and sponges for haemostasis, collagen membranes for wound covering or implantation, and injections of soluble collagen in plastic surgery. Nonetheless, it has not previously been recognised that a collagen membrane would be suitable for guided tissue regeneration.

Various artificial collagen-containing membranes have been described in the prior art and proposed for the dressing or coverage of wounds. Thus, in WO-A-88/08305 (The Regents of The University of California) there is described a composite skin replacement which consists of a layer of human epidermal cells together

with a layer of a biosynthetic membrane which may be formed of collagen and mucopolysaccharides. However, the collagen/mucopolysaccharide portion is of uniform texture throughout and does not exhibit the properties of the membrane proposed herein for guided tissue regeneration. Furthermore, such membranes are strongly immuno-reactive and can only be used on the donor of the cells. Another artificial collagen-containing membrane is described in DE-A-2631909 (Massachusetts Institute of Technology). This membrane consists of a minimum of two layers, the first layer being a combination of collagen and mucopolysaccharides and the second layer being a synthetic polymer such as a polyacrylate. However, this membrane is totally non-resorbable, the collagenous layer being so tightly cross-linked internally that resorption cannot occur.

The membrane for use in the present invention may be derived directly from naturally occurring membranes which, as far as possible, retain their natural collagen structure. The membrane sources include sections of hide with a grain side, tendons, various animal membranes etc. A preferred source of membrane is the naturally occurring peritoneum membrane, especially taken from calves or piglets. Peritoneum membranes from young pigs aged 6-7 weeks old (weighing 60-80 kg) are especially preferred.

The membrane material for use in the present invention should preferably consist of pure, native (not denatured), insoluble collagen. However, in an animal's body, collagen is accompanied by a number of substances which have undesirable chemical, physical and/or physiological properties. The collagen therefore has to be freed from these substances by purification. Since the nature of such substances varies considerably, enzymatic purification is virtually impossible. It is thus preferable to carry out purification chemically, taking care to minimise any alteration to the chemical

structure of the collagen and thus to maintain its original native properties.

According to a further aspect of the present invention we provide a method of preparing a membrane as described above in which a mammalian collagen membrane having a smooth face and a fibrous face is subjected to treatment with alkali to saponify fats and degrade alkali sensitive substances and then acidified to degrade acid sensitive substances, followed by washing, drying, degreasing and optional cross-linking.

During purification, the following changes occur:


- non-collagenous proteins are eliminated
- glycosaminoglycans and proteoglycans are dissolved and eliminated
- the fats are partially saponified, and totally eliminated.

During such treatment, the following undesirable changes may also occur:

- hydrolysis of the amide groups of asparagine and glutamine
- a shift in the isoelectric point
- cleavage of crosslinking bonds
- transamidation, with the formation of isopeptides
- racemisation of amino acids
- cleavage of peptide bonds.

The level of amide nitrogen in the membrane serves as an indicator of these changes. For example, it has been found that if the amide nitrogen content falls by about half (ie. from 0.7 mmol/g to 0.35 mmol/g) then more than 95% of the collagen is still present in its native state. The basis of this measurement is the hydrolysis of amide groups in the amino acids asparagine and glutamine:

- 6 -



The degree of purification of the collagen can be determined by amino acid analysis. Collagen is hydrolysed to form amino acids, which means that this analysis indicates pure collagen and elimination of non-collagenous proteins but not the denaturing of collagen.

Together with amino acid analysis of the collagen, the glycosamine and proteoglycans content can also be analysed. These contaminants are hydrolysed and the monomeric glycosamine and hexosamine content of the membrane is determined by chromatography. It has been found that the quantity of glycosamine and galactosamine after purification is approximately 1 molecule to 10,000 molecules of amino acids.

In one method of preparing the membranes, the raw materials are first treated with alkali. For this step, solutions of NaOH are used in concentrations from 0.2 - 4% by weight. The fats are saponified, and any accompanying proteins sensitive to alkalis are eliminated together with any other substances sensitive to alkalis, such as glycosaminoglycans, proteoglycans, etc. The process is controlled by determining the amide nitrogen. At the end of the alkaline treatment the level of amide nitrogen should be between 0.3 and 0.5 mmol/g.

The second step is the treatment of the material with inorganic acid, usually HCl. Acid-sensitive contaminants are eliminated, the fibres are greatly swollen and in this way the fibrous structure is loosened. Acidification is continued until the material

is homogeneously acidified.

After this, the material is washed. It has proved useful to wash the material until the pH has changed from 0.5 - 1.5 (during acidification with HCl) to between 2.5 - 3.5. The washing is preferably carried out with distilled water.

The swollen material can now be levelled out (split), to achieve a uniform thickness. Further steps include a de-swelling operation, neutralisation and thorough washing of the material. For this, the material is first treated with an acidic (pH 2.8 - 3.5) common salt solution (concentration 5 - 10% by weight). The material is thus completely de-swollen. It is then washed with excess of slightly alkaline distilled water until the pH of the material reaches 5.8 - 6.5. The material is then thoroughly washed with distilled water (pH 6.0). This brings to an end the first phase of production, namely purification. This is followed by drying and degreasing.

The material is dried by repeated washing with acetone. This causes shrinkage of the collagen fibres and, as a result, an open structure remains. The degreasing is carried out with n-hexane. This eliminates the last traces of hydrophobic substances from the material.

In this regard reference may also be made to US-A-5028695 (EP-A-331786) describing the production of membranes suitable for use in the present invention.

The dry thickness of the membrane for use in guided tissue regeneration according to the present invention should ideally be between 0.1 and 1.0 mm but can be influenced by swelling of the material.

The membrane may thus be split or sectioned to achieve the required thickness, provided that the dual textures of the membrane are maintained.

The membrane may further be treated to adapt its properties to suit a particular wound type. Thus, the

collagen of the membrane may be cross-linked to stabilise the membrane and reduce the rate of absorption by the body.

All the crosslinking agents known hitherto and used for medical products can be used for the membranes (e.g. formaldehyde, glutardialdehyde, hexamethylenediisocyanate, dicyclohexylcarbodiimide, etc.). Physically, crosslinking may be carried out by the application of heat. In this case the crosslinking effect is admittedly smaller but is sufficient for most applications. Conveniently the collagen of the membrane is physically crosslinked by heating to 100-120°C (for 30 minutes to 5 hours), thereby extending the degradation time.

Conveniently the degree of cross-linking introduced will be such that the rate of reabsorption of the membrane correlates with the growth of the new tissue and healing of the wound. For example, osteocytes take approximately 6 weeks to regenerate a tooth cavity and thus a membrane which is absorbed in a period of 8-12 weeks would be suitable for lining that wound type. Clearly the membrane should not be heavily cross-linked otherwise the rate of absorption would be too slow and in extreme cases the membrane becomes non-absorbable.

One other modification which may be made to the membrane is to coat or impregnate the fibrous side with a glycosaminoglycan (GAG) such as hyaluronic acid, chondroitin sulphate, dermatan sulphate or keratan sulphate.

In native collagen tissues GAGs occur, in part, as a component of proteoglycans (PGs). Chondroitin sulphate, dermatan sulphate and keratan sulphate are covalently bonded to the core protein of PGs while hyaluronic acid is linked by non-covalent bonds. For use according to the invention, the GAGs may be added in the form of PGs. However, this is less preferred in view of potential immunological problems which might be

caused by the protein content of the PGs.

- Glycosaminoglycans such as hyaluronic acid and proteoglycans are important as regulatory molecules which affect tissue structure. They have a favourable influence on:

- cell infiltration
- the formation and degradation of the fibrin matrix
- swelling of the matrix
- phagocytosis
- vascularisation

Shortly after injury the content of GAG in a wound increases. Hyaluronic acid and related GAGs bind to fibrin and form a three dimensional matrix (clot) which is interwoven within the fibrin matrix. The original fibrin matrix is thereby deformed, swells and becomes more porous. This permits better and faster infiltration and migration of the cells into the matrix.

Hyaluronic acid and fibrinogen react specifically with one another, even if one or other molecule is in a solid state.

In the inflammatory stage of injury hyaluronic acid stimulates granulocyte function, alters the properties of the surface of polymorphonuclear leukocytes and regulates the phagocytosis activity of cells.

~~During the conversion and breakdown of the~~ hyaluronic acid fibrin matrix, smaller fragments of hyaluronic acid are produced. Small fragments of hyaluronic acid stimulate the construction of new blood vessels.

Additionally, GAGs such as hyaluronic acid make collagen incapable of provoking an immune reaction in a host animal. In order to achieve this the collagen must be reacted with at least one weight percent of GAG acid.

GAGs and PGs are carrier for structural and biologically active proteins. It has been found that GAG protein complex plays a very important part in scar-free wound healing in the fetus.

For these reasons impregnation of the collagen membrane with GAGs such as hyaluronic acid causes improved tissue regeneration within a wound or bone lesion.

In a further aspect, the present invention provides a membrane for use in guided tissue regeneration, one side of said membrane having a smooth texture, the opposite side having a fibrous texture, said membrane being impregnated with one or more GAGs or PGs.

Preferably, the GAG and/or PG concentration increases through the thickness of the membrane, with the highest concentration of GAG or PG being on the fibrous side of the membrane.

The GAG or PG material may be introduced into the membrane as a gel which is spread onto the fibrous side of the membrane and then allowed to dry. This approach achieves a decreasing concentration gradient down into the membrane whilst the GAG or PG does not completely penetrate through the membrane.

Whilst we do not wish to be bound by theoretical considerations, it is believed that the chains of the high MW GAGs and PGs act to guide the new cells down onto the membrane surface which can then act as a support for cell growth.

It is thus particularly beneficial that the fibrous side of the membrane is in the form of a composite matrix including PGs and/or GAGs.

Hyaluronic acid and other GAGs naturally in the body with the skin containing 19% and the peritoneum 13% (by weight) hyaluronic acid. As naturally occurring substances GAGs do not cause any problems regarding toxicity or resorption, but rather are believed to act as a natural nutritional substance for the cells.

- 11 -

Hyaluronic acid and other GAGs are produced industrially and are thus readily available in commercial quantities.

Conveniently the membrane according to the present invention contains 0.1 to 30% by weight of a GAG or PG, for example hyaluronic acid, for example 2-10% by weight.

If required other pharmaceuticals such as antibiotics (eg. tetracycline), chemotherapeutics (eg. taurolidine) and other drugs may also be incorporated into the membrane.

The present invention also provides the use of the resorbable membrane described above, optionally including one or more PGs or one or more GAGs such as hyaluronic acid as additive in the manufacture of a component matrix for use as a guided tissue regeneration implant.

One particularly beneficial application of the membranes in guided tissue regeneration is after orofacial or dental surgery. Here it is often important for bone regeneration to take place, for example after partial removal of a tooth root or section of jaw. The constricted orofacial area makes surgery difficult and thus a non-toxic fully resorbable implant for guided tissue regeneration is highly advantageous. In addition, the nature of the membrane is particularly suited to encouraging the growth of osteocytes (bone tissue).

The present invention further provides a method of treating wounds or lesions of the human or non-human animal (preferably mammalian) body, said method comprising application of a membrane as described above to the wound or lesion, said membrane being orientated so that the fibrous side faces the area where tissue regeneration is required. The method is particularly suitable for the treatment of orofacial wounds or lesions.

Figure 1 shows a membrane according to the present

- 12 -

invention in use for bone regeneration of a tooth (1) which has suffered heavy bone loss around the root (2) resulting in a cavity (3) normally filled by healthy root. The root (2) protrudes through a layer of connective tissue or gum (4) into a bone socket (5). To prevent ingrowth of connective tissue (4) into cavity (3) a membrane cover (6) is placed around the outermost edge of the wound. The membrane (6) extends all round the wound cavity (3). The membrane (6) has a smooth side (7) which faces away from cavity (3) and a fibrous side (8) which faces into cavity (3). The fibrous side (8) provides a supporting surface for new cells growing outward from root (2), whereas the smooth side (7) of the membrane (6) prevents cells of connective tissue (4) invading the wound cavity. Membrane (6) is resorbed slowly back into the body, optimally membrane absorption correlates to the time taken for wound healing.

The present invention may be further illustrated by means of the following non-limiting Example:

Example

The peritoneal membranes from young calves are completely freed from flesh and grease by mechanical means, washed under running water and treated with 2% NaOH solution for 12 hours. The membranes are then washed under running water and acidified with 0.5% HCl. After the material has been acidified through its entire thickness (about 3 hours) the material is washed until a pH of 3.5 is obtained. The material is then shrunk with 7% saline solution, neutralised with 1% NaHCO₃ solution and washed under running water. The material is then dehydrated with acetone and degreased with N-hexane. The amide nitrogen content of the material is 0.47 mMole/g.

Determination of the amide nitrogen content:

(Eastoe, E; Courts, A; Practical Analytical Methods for Connective Tissue Proteins (1963)).

Reagents

1. 2 N HCl (160 ml of conc. HCl made up to 1 litre)
2. 0.05 M Borax - 0.15 N NaOH solution (19.1 g $\text{Na}_2\text{B}_4\text{O}_7 \cdot 10 \text{ H}_2\text{O}$) + 6 g NaOH in 1 litre, topped up with cold distilled H_2O .
3. Indicator - mixed in ethanol (0.33% methylene blue + 0.05% methylene red)
4. 1% boric acid with the indicator
10 g boric acid in 1 litre distilled cold H_2O
8 ml indicator
0.7 ml 0.1 N - NaOH
5. 0.01 N HCl

Method

1. 1 g of dried collagen mass is dispersed in 50 ml of 2N HCl and boiled for 1 hour. The volume is made up to 50 ml at 20°C.
2. 5 ml of this dispersion are placed in a microkjeldahl flask, together with 20 ml of solution 2; the mixture is distilled in 20 ml of solution 4. Distillation takes 6 minutes.
3. The solution is titrated with reagent 5.

Calculation

ml of acid consumption x 20 = mmol % amide N

Example

1.36 ml of 0.01N HCl x 20 = 27.2 mmol %
= 0.27 mmol/g amide N

Claims

1. A resorbable collagen membrane for use in guided tissue regeneration wherein one face of said membrane is fibrous thereby allowing cell growth thereon and the opposite face of said membrane is smooth, thereby inhibiting cell adhesion thereon.
2. A membrane as claimed in claim 1 which is derived from a natural collagen membrane.
3. A membrane as claimed in claim 2 derived from mammalian pericardium or placenta membrane or basal membrane.
4. A membrane as claimed in claim 3 which is derived from calves or piglets.
5. A membrane as claimed in claim 4 which is derived from 6-7 week old piglets.
6. A membrane as claimed in any of claims 1 to 5 which is substantially free from fat.
7. A membrane as claimed in any of claims 1 to 6 which has a thickness of 0.1 to 1.0 mm when dry.
8. A membrane as claimed in any of claims 1 to 7 in which the collagen is cross-linked without becoming non-resorbable.
9. A membrane as claimed in any of claims 1 to 8 in which the fibrous side is impregnated with a glycosaminoglycan or proteoglycan.
10. A membrane as claimed in claim 9 in which the fibrous side is impregnated with hyaluronic acid.

11. A membrane as claimed in claim 9 in which the fibrous side is impregnated with chondroitin sulphate, dermatan sulphate and/or keratan sulphate.
12. A membrane as claimed in any of claims 9 to 11 in which the membrane contains 0.1 to 30.0% by weight of glycosaminoglycan and/or proteoglycan.
13. A membrane as claimed in any of the preceding claims containing one or more pharmaceuticals.
14. A membrane as claimed in claim 13 containing taurolidine.
15. Use of a membrane as claimed in claim 1 in the manufacture of a guided tissue regeneration implant.
16. A method of treating wounds or lesions of the human or non-human animal body comprising application of a membrane as claimed in claim 1 to the wound or lesion, said membrane being so oriented that the fibrous side faces the area where tissue regeneration is required.
17. A method as claimed in claim 16 in which the said tissue is bone.
18. A method as claimed in claim 17 in which the wound or lesion is in the orofacial region.
19. A method of preparing a membrane as claimed in claim 1 in which a mammalian collagen membrane having a smooth face and a fibrous face is subjected to treatment with alkali to saponify fats and degrade alkali sensitive substances and then acidified to degrade acid sensitive substances, followed by washing, drying, degreasing and optional cross-linking.

20. . A method as claimed in claim 19 in which, a glycosaminoglycan is impregnated into the fibrous side of said membrane.

1/1




FIG.1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 95/00008

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61L31/00 A61L15/32 A61L15/40 A61L27/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE,A,36 07 075 (AMERICAN HOSPITAL SUPPLY) 4 September 1986	1-4, 15-17
Y	see page 8, line 29 - line 33 see page 10, line 32 - page 11, line 5; claims 16-21	6, 19
Y	EP,A,0 331 786 (CHEMOKOL) 13 September 1989 cited in the application see claims 1,7,8	6, 19
A	WO,A,93 10722 (RESEARCH DEVELOPMENT FOUNDATION) 10 June 1993 see page 4, line 13 - line 21; example 4	1-4,8
A	WO,A,93 02718 (COLETICA) 18 February 1993 see the whole document	1-4,8
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

5 April 1995

Date of mailing of the international search report

27.04.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Peltre, C

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/GB 95/00008

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO,A,90 13302 (BRIGHAM AND WOMEN'S HOSPITAL) 15 November 1990 see claims 6-8</p> <p>-----</p>	1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/GB 95/00008

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
DE-A-3607075	04-09-86	US-A-	4674488	23-06-87
		GB-A-	2174909	19-11-86
EP-A-0331786	13-09-89	AT-T-	109491	15-08-94
		DE-D-	3850956	08-09-94
		JP-A-	2063462	02-03-90
		JP-B-	6009606	09-02-94
		US-A-	5028695	02-07-91
WO-A-9310722	10-06-93	AU-A-	3224593	28-06-93
		CA-A-	2124190	10-06-93
		CN-A-	1079912	29-12-93
		EP-A-	0614345	14-09-94
		FI-A-	942425	25-05-94
		JP-T-	7501465	16-02-95
		NO-A-	941917	24-05-94
WO-A-9302718	18-02-93	FR-A-	2679778	05-02-93
		AU-A-	2474592	02-03-93
		EP-A-	0641225	08-03-95
		FI-A-	940472	01-02-94
		NO-A-	940279	30-03-94
WO-A-9013302	15-11-90	AU-A-	5654990	29-11-90

Form PCT/ISA/210 (patent family annex) (July 1992)